TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Pfizer Inc(PFE)

Jun 14, 2012
Model price $26.71, 21% upside. This market is looking for yield, which is 3.9% here. A perfect candidate if you want to hide in equities. Likes this space also.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.56

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Track your Stocks in your Watch List
HOLD

Pfizer Inc(PFE)

Jun 07, 2012
Generally, healthcare sector tends to be more defensive and stable. Nice yield of about 4%. Also expects there are some catalysts around the areas that this company might change or spin off, which could enhance shareholder value
Photo of Stan WongStan Wong
Owned
Unlock Rating
$21.94

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 18, 2012
We are in an environment where dividends count. This one gives a 3% plus yield. Any time the market goes through deflationary pockets, money rotates back to consumer staples, drugs, etc.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.57

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 20, 2012
Thinks there is lots of potential. Drug stocks are severely under owned. The patent cliff that people were looking for has already happened and they are looking forward to the new drugs that are coming along. The CEO decided PFE was too big so any big drug coming along would have to be mammoth to have an impact, so he is actively talking about selling off some parts of the business, such as the Animal health. Nice yield. Earnings start to grow after next year or two.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.80

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 13, 2012
Prefers Teva to Pfizer. PFE does not have the growth profile. 11 or 12 times earnings. Abbot labs are good too. If it falls 10% he would be all over it.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$22.01

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2012
(A Top Pick Feb 28/11. Up 13.97%.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.30

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 02, 2012
Dividend is safe, growth prospects of many of the large Parma are very muted.
Photo of Don LatoDon LatoUnlock Rating
$21.11

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 01, 2012
Pharma: The trend is really looking quite good. Hasn’t looked at Pfizer in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.
Photo of Mike S. Newton, CIM FCSIMike S. Newton, CIM FCSIUnlock Rating
$21.31

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 26, 2012
One of the defensive stocks that did very, very well last year. Starting to see it roll over a little bit. Technically speaking it still looks pretty sound with the 200 day moving upwards and the 50 day moving across the 200 day very recently. Dividend is about 4%. Doesn't look at this as a tremendous growing company but is in the mid to high single digit range.
Photo of Stan WongStan Wong
No
Unlock Rating
$21.63

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 09, 2012
(Market Call Minute.) Good dividend yield. Company is buying back a lot of stocks. Well-run in a very tough business.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$21.82

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2012
His model price is $26.88, which is a 22% positive differential. Yielding 4%. This happens to be one that has valuation and yield together, which is great. His target would be about $26.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.77

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2011
Pharmaceutical space is tough. Lipitor is a drug that is going off-patent which will reduce their income.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$18.45

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 21, 2011
The 3 sectors hated sectors in the US are financials, healthcare and technology. They have done a lot of smart things recently. They increased the dividend and announced a share buyback. Valuation is quite cheap and he is looking at this one.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$18.96

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 15, 2011
A good space. Defensive name. Prefers JNJ. Seeing higher lows this year. Could come down to a higher low. Ranked 5th on his list. Would hold it.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$19.87

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 24, 2011
The whole pharma business is challenged. PFE is predicting lower revenues next year. Management is talking about breaking up the company. With Lipitor patent expiring, he would just sell it.
Photo of Gordon ReidGordon ReidUnlock Rating
$19.36

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 421 to 435 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like